Premium
Translational research of ghrelin
Author(s) -
Ueno Hiroaki,
Shiiya Tomomi,
Nakazato Masamitsu
Publication year - 2010
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2010.05509.x
Subject(s) - ghrelin , orexigenic , appetite , endocrinology , medicine , cachexia , energy homeostasis , amylin , anorectic , anorexia , hormone , obesity , cancer , neuropeptide , food intake , neuropeptide y receptor , receptor , diabetes mellitus , islet
Gastrointestinal peptides play important roles regulating feeding and energy homeostasis. Most gastrointestinal peptides including glucagon like peptide‐1, peptide YY, amylin, and oxytomodulin are anorectic, and only ghrelin is an orexigenic peptide. Ghrelin increases appetite, modulates energy balance, suppresses inflammation, and enhances growth hormone secretion. Given its diversity of functions, ghrelin is expected be an effective therapy for lean patients with cachexia caused by chronic heart failure, chronic respiratory disease, anorexia nervosa, functional dyspepsia, and cancer. Clinical trials have demonstrated that ghrelin effectively increases lean body mass and activity in cachectic patients. Ghrelin interrupts the vicious cycle of the cachectic paradigm through its orexigenic, anabolic, and anti‐inflammatory effects, and ghrelin administration may improve the quality of life of cachectic patients. We discuss the significant roles of ghrelin in the pathophysiology of cachectic diseases and the possible clinical applications of ghrelin.